{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:47:33Z","timestamp":1791182853138,"version":"4.1.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.autrev.2014.11.004","type":"journal-article","created":{"date-parts":[[2014,11,17]],"date-time":"2014-11-17T01:21:44Z","timestamp":1416187304000},"page":"231-245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Systematic review: New serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes"],"prefix":"10.1016","volume":"14","author":[{"given":"J.","family":"Bonneau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dumestre-Perard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rinaudo-Gaujous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Genin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sparrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Roblin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2014.11.004_bb0005","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jtbi.2003.11.002","article-title":"A primary dysregulation in the immunoregulatory role of the intestinal mucosal epithelial cell in inflammatory bowel disease pathogenesis? Biology of inflammatory response as tissue pattern entities in Crohn's versus ulcerative colitis","volume":"227","author":"Agius","year":"2004","journal-title":"J Theor Biol"},{"key":"10.1016\/j.autrev.2014.11.004_bb0010","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(07)60750-8","article-title":"Inflammatory bowel disease: cause and immunobiology","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2014.11.004_bb0015","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1053\/j.gastro.2007.11.059","article-title":"Microbial influences in inflammatory bowel diseases","volume":"134","author":"Sartor","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2014.11.004_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2013.06.007","article-title":"Immunity, autoimmunity and inflammatory bowel disease","volume":"13","author":"Cassinotti","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.11.004_bb0025","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.autrev.2014.01.029","article-title":"Diagnosis and classification of Crohn's disease","volume":"13","author":"Laass","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.11.004_bb0030","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.autrev.2014.01.028","article-title":"Diagnosis and classification of ulcerative colitis","volume":"13","author":"Conrad","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.11.004_bb0035","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.autrev.2013.06.002","article-title":"Optimizing anti-TNF treatments in inflammatory bowel disease","volume":"13","author":"Ben-Horin","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.11.004_bb0040","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1111\/j.1572-0241.2006.00840.x","article-title":"Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease","volume":"101","author":"Reese","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2014.11.004_bb0045","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1542-3565(03)00321-5","article-title":"Utility of serum antibodies in determining clinical course in pediatric Crohn's disease","volume":"2","author":"Desir","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2014.11.004_bb0050","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/j.1572-0241.2002.05689.x","article-title":"Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease","volume":"97","author":"Esters","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2014.11.004_bb0055","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4065\/71.5.431","article-title":"Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study","volume":"71","author":"Sandborn","year":"1996","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.autrev.2014.11.004_bb0060","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1373\/clinchem.2005.058560","article-title":"Serologic markers in inflammatory bowel disease","volume":"52","author":"Bossuyt","year":"2006","journal-title":"Clin Chem"},{"key":"10.1016\/j.autrev.2014.11.004_bb0065","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1128\/IAI.68.3.1542-1548.2000","article-title":"Colonic bacteria express an ulcerative colitis pANCA-related protein epitope","volume":"68","author":"Cohavy","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.autrev.2014.11.004_bb0070","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1053\/gast.2000.8519","article-title":"Identification of a novel bacterial sequence associated with Crohn's disease","volume":"119","author":"Sutton","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2014.11.004_bb0075","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1128\/IAI.70.12.6567-6575.2002","article-title":"Pseudomonas fluorescens encodes the Crohn's disease-associated I2 sequence and T-cell superantigen","volume":"70","author":"Wei","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.autrev.2014.11.004_bb0080","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1172\/JCI200420295","article-title":"Bacterial flagellin is a dominant antigen in Crohn disease","volume":"113","author":"Lodes","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2014.11.004_bb0085","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1053\/j.gastro.2003.11.015","article-title":"Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease","volume":"126","author":"Mow","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2014.11.004_bb0090","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/01.mib.0000235833.47423.d7","article-title":"Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease","volume":"12","author":"Spivak","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2014.11.004_bb0095","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1572-0241.2006.00456.x","article-title":"Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression","volume":"101","author":"Dubinsky","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2014.11.004_bb0100","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1053\/gast.2002.35379","article-title":"Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens","volume":"123","author":"Landers","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2014.11.004_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.dld.2013.01.017","article-title":"Increased antibody response to microbial antigens in patients with Crohn's disease and their unaffected first-degree relatives","author":"Michielan","year":"2013","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2014.11.004_bb0110","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1111\/j.1572-0241.2004.40369.x","article-title":"Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype","volume":"99","author":"Zholudev","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2014.11.004_bb0115","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.cgh.2008.04.032","article-title":"Increased immune reactivity predicts aggressive complicating Crohn's disease in children","volume":"6","author":"Dubinsky","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2014.11.004_bb0120","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1111\/j.1572-0241.2004.40417.x","article-title":"Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2\/CARD15 genotype","volume":"99","author":"Arnott","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2014.11.004_bb0125","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1053\/j.gastro.2006.11.013","article-title":"NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives","volume":"132","author":"Devlin","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2014.11.004_bb0130","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1097\/MIB.0b013e318281f2a1","article-title":"Serum antibodies associated with complex inflammatory bowel disease","volume":"19","author":"Elkadri","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2014.11.004_bb0135","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/ibd.20831","article-title":"Age of diagnosis influences serologic responses in children with Crohn's disease: a possible clue to etiology?","volume":"15","author":"Markowitz","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2014.11.004_bb0140","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1053\/j.gastro.2006.02.013","article-title":"Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease","volume":"130","author":"Mei","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2014.11.004_bb0145","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1097\/MEG.0b013e328365a364","article-title":"The clinical significance of antimicrobial serologic responses within an Irish Crohn's disease population","volume":"25","author":"O'Donnell","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2014.11.004_bb0150","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/ibd.20106","article-title":"Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations","volume":"13","author":"Papadakis","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2014.11.004_bb0155","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/MPG.0b013e31812f7f6e","article-title":"Antibodies to Escherichia coli outer membrane porin C in the absence of anti-Saccharomyces cerevisiae antibodies and anti-neutrophil cytoplasmic antibodies are an unreliable marker of Crohn disease and ulcerative colitis","volume":"45","author":"Davis","year":"2007","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.autrev.2014.11.004_bb0160","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1007\/s10620-012-2050-6","article-title":"ASCA IgG and CBir antibodies are associated with the development of Crohn's disease and fistulae following ileal pouch-anal anastomosis","volume":"57","author":"Coukos","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.autrev.2014.11.004_bb0165","doi-asserted-by":"crossref","first-page":"507-12.e1","DOI":"10.1016\/j.cgh.2011.09.016","article-title":"Antimicrobial antibodies are associated with a Crohn's disease-like phenotype after ileal pouch-anal anastomosis","volume":"10","author":"Tyler","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2014.11.004_bb0170","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/00365521.2011.639080","article-title":"Seroreactivity to E. coli outer membrane protein C antibodies in active inflammatory bowel disease; diagnostic value and correlation with phylogroup B2 E. coli infection","volume":"47","author":"Petersen","year":"2012","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.autrev.2014.11.004_bb0175","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/01.MIB.0000218765.84087.42","article-title":"Elevated serum anti-I2 and anti-OmpW antibody levels in children with IBD","volume":"12","author":"Iltanen","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2014.11.004_bb0180","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1002\/ibd.21661","article-title":"Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior","volume":"17","author":"Lichtenstein","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2014.11.004_bb0185","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1053\/j.gastro.2005.03.046","article-title":"Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease","volume":"128","author":"Targan","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2014.11.004_bb0190","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.cgh.2008.01.002","article-title":"Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis","volume":"6","author":"Fleshner","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2014.11.004_bb0195","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10620-013-2866-8","article-title":"Serologic markers associated with development of Crohn's disease after ileal pouch anal anastomosis for ulcerative colitis","volume":"59","author":"Truta","year":"2014","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.autrev.2014.11.004_bb0200","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/apt.12368","article-title":"Predicting complicated Crohn's disease and surgery: phenotypes, genetics, serology and psychological characteristics of a population-based cohort","volume":"38","author":"Ryan","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2014.11.004_bb0205","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/ibd.20892","article-title":"Phenotypic associations of Crohn's disease with antibodies to flagellins A4-Fla2 and Fla-X, ASCA, p-ANCA, PAB, and NOD2 mutations in a Swiss cohort","volume":"15","author":"Schoepfer","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2014.11.004_bb0210","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1053\/j.gastro.2006.04.030","article-title":"Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease","volume":"131","author":"Dotan","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2014.11.004_bb0215","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1572-0241.2007.01652.x","article-title":"New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2\/CARD15 genotype in a Hungarian IBD cohort","volume":"103","author":"Papp","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2014.11.004_bb0220","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1136\/gut.2008.162495","article-title":"Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease","volume":"58","author":"Roggenbuck","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2014.11.004_bb0225","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.crohns.2012.10.011","article-title":"Autoantibodies against exocrine pancreas in Crohn's disease are directed against two antigens: the glycoproteins CUZD1 and GP2","volume":"7","author":"Komorowski","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2014.11.004_bb0230","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.autrev.2011.09.004","article-title":"Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies","volume":"11","author":"Bogdanos","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.11.004_bb0235","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.4049\/jimmunol.1103190","article-title":"Identification of pancreatic glycoprotein 2 as an endogenous immunomodulator of innate and adaptive immune responses","volume":"189","author":"Werner","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2014.11.004_bb0240","first-page":"187","article-title":"Glycoprotein 2 antibodies in Crohn's disease","volume":"vol. 60","author":"Roggenbuck","year":"2013"},{"key":"10.1016\/j.autrev.2014.11.004_bb0245","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1471-230X-9-58","article-title":"The pancreatic zymogen granule membrane protein, GP2, binds Escherichia coli type 1 Fimbriae","volume":"9","author":"Yu","year":"2009","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.autrev.2014.11.004_bb0250","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature08529","article-title":"Uptake through glycoprotein 2 of FimH+ bacteria by M cells initiates mucosal immune response","volume":"462","author":"Hase","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2014.11.004_bb0255","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.cca.2010.12.029","article-title":"Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease","volume":"412","author":"Roggenbuck","year":"2011","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.autrev.2014.11.004_bb0260","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1586\/egh.10.73","article-title":"GM-CSF: a role in immune and inflammatory reactions in the intestine","volume":"4","author":"Egea","year":"2010","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2014.11.004_bb0265","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/ibd.21072","article-title":"Granulocyte-macrophage colony-stimulating factor elicits bone marrow-derived cells that promote efficient colonic mucosal healing","volume":"16","author":"Bernasconi","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2014.11.004_bb0270","first-page":"1702","article-title":"GM-CSF produced by nonhematopoietic cells is required for early epithelial cell proliferation and repair of injured colonic mucosa","volume":"190","author":"Egea","year":"2013","journal-title":"J Immunol Baltim Md 1950"},{"key":"10.1016\/j.autrev.2014.11.004_bb0275","doi-asserted-by":"crossref","first-page":"G455","DOI":"10.1152\/ajpgi.00409.2013","article-title":"Granulocyte macrophage colony-stimulating factor and the intestinal innate immune cell homeostasis in Crohn's disease","volume":"306","author":"D\u00e4britz","year":"2014","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.autrev.2014.11.004_bb0280","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1056\/NEJMoa041109","article-title":"Sargramostim for active Crohn's disease","volume":"352","author":"Korzenik","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2014.11.004_bb0285","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/cei.12076","article-title":"Paediatric Crohn disease patients with stricturing behaviour exhibit ileal granulocyte-macrophage colony-stimulating factor (GM-CSF) autoantibody production and reduced neutrophil bacterial killing and GM-CSF bioactivity","volume":"172","author":"Jurickova","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2014.11.004_bb0290","doi-asserted-by":"crossref","first-page":"1261-71.e3","DOI":"10.1053\/j.gastro.2008.12.046","article-title":"Granulocyte-macrophage colony-stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn's disease","volume":"136","author":"Han","year":"2009","journal-title":"Gastroenterology"},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2014.11.004_bb0295","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00508-010-1344-y","article-title":"Autoantibodies pANCA, GAB and PAB in inflammatory bowel disease: prevalence, characteristics and diagnostic value","volume":"122","author":"Homsak","year":"2010","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.autrev.2014.11.004_bb0300","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/01.MIB.0000182872.76434.8c","article-title":"A comparative study of goblet cell and pancreatic exocine autoantibodies combined with ASCA and pANCA in Chinese and Caucasian patients with IBD","volume":"11","author":"Lawrance","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2014.11.004_bb0305","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1445-5994.1992.tb04865.x","article-title":"Autoantibodies to neutrophil cytoplasmic (ANCA) and endothelial cell surface antigens (AECA) in chronic inflammatory bowel disease","volume":"22","author":"Romas","year":"1992","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.autrev.2014.11.004_bb0310","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0378-1135(00)00334-5","article-title":"Specific seroreactivity of Crohn's disease patients against p35 and p36 antigens of M. avium subsp. paratuberculosis","volume":"77","author":"Naser","year":"2000","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.autrev.2014.11.004_bb0315","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.1128\/IAI.69.10.6044-6054.2001","article-title":"Molecular cloning of a Bacteroides caccae TonB-linked outer membrane protein identified by an inflammatory bowel disease marker antibody","volume":"69","author":"Wei","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.autrev.2014.11.004_bb0320","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/ibd.20328","article-title":"Autoantibodies against ubiquitination factor E4A (UBE4A) are associated with severity of Crohn's disease","volume":"14","author":"Sakiyama","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2014.11.004_bb0325","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/ajg.2013.354","article-title":"EMerging BiomARKers in inflammatory bowel disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging","volume":"108","author":"Faubion","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2014.11.004_bb0330","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.3748\/wjg.v19.i37.6207","article-title":"Inflammatory bowel disease serology in Asia and the West","volume":"19","author":"Prideaux","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.autrev.2014.11.004_bb0335","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/ibd.21854","article-title":"Clinical utility of anti-glycan antibodies in pediatric Crohn's disease in comparison with an adult cohort","volume":"18","author":"Rieder","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2014.11.004_bb0340","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/ibd.21046","article-title":"Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn's disease behavior","volume":"16","author":"Rieder","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2014.11.004_bb0345","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s10620-010-1328-9","article-title":"Antiglycan antibodies in Greek patients with inflammatory bowel disease","volume":"56","author":"Koutroubakis","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.autrev.2014.11.004_bb0350","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/ibd.20368","article-title":"Antiglycan antibodies as serological markers in the differential diagnosis of inflammatory bowel disease","volume":"14","author":"Simondi","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2014.11.004_bb0355","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ajg.2009.79","article-title":"Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype","volume":"104","author":"Seow","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2014.11.004_bb0360","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/ibd.21179","article-title":"Serum anti-glycan antibodies predict complicated Crohn's disease behavior: a cohort study","volume":"16","author":"Rieder","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2014.11.004_bb0365","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/MEG.0b013e32832f5c7e","article-title":"Anticarbohydrate antibodies as markers of inflammatory bowel disease in a Central European cohort","volume":"22","author":"Malickova","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2014.11.004_bb0370","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1136\/gut.2007.125468","article-title":"Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease","volume":"56","author":"Henckaerts","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2014.11.004_bb0375","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s12223-008-0058-2","article-title":"Antilaminaribioside and antichitobioside antibodies in inflammatory bowel disease","volume":"53","author":"Rejchrt","year":"2008","journal-title":"Folia Microbiol (Praha)"},{"key":"10.1016\/j.autrev.2014.11.004_bb0380","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1136\/gut.2006.108043","article-title":"New serological markers in inflammatory bowel disease are associated with complicated disease behaviour","volume":"56","author":"Ferrante","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2014.11.004_bb0385","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1002\/ibd.22862","article-title":"Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: a systematic review and meta-analysis","volume":"18","author":"Kaul","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2014.11.004_bb0390","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/j.1572-0241.2007.01648.x","article-title":"Detection of antisynthetic mannoside antibodies (ASigmaMA) reveals heterogeneity in the ASCA response of Crohn's disease patients and contributes to differential diagnosis, stratification, and prediction","volume":"103","author":"Vandewalle-El Khoury","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2014.11.004_bb0395","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/gut.2010.233148","article-title":"Antibodies to GP2, the major zymogen granule membrane glycoprotein, in inflammatory bowel diseases","volume":"61","author":"Be\u00e9ck","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2014.11.004_bb0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/640835","article-title":"Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn's disease","volume":"2012","author":"Pavlidis","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.autrev.2014.11.004_bb0405","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1471-230X-12-102","article-title":"Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease","volume":"12","author":"Bogdanos","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.autrev.2014.11.004_bb0410","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.cca.2011.02.005","article-title":"Antibodies to glycoprotein 2 (GP2) in patients with inflammatory bowel diseases from UK","volume":"412","author":"Pavlidis","year":"2011","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.autrev.2014.11.004_bb0415","doi-asserted-by":"crossref","first-page":"127","DOI":"10.15403\/jgld.2014.1121.232.sg1","article-title":"Increased IgA glycoprotein-2 specific antibody titres in refractory celiac disease","volume":"23","author":"Gross","year":"2014","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.autrev.2014.11.004_bb0420","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.cca.2012.01.005","article-title":"Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, in patients with gluten-sensitive enteropathy: a possible serological trap","volume":"413","author":"Bonaci-Nikolic","year":"2012","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.autrev.2014.11.004_bb0425","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1016\/j.crohns.2012.12.013","article-title":"Loss of tolerance to one or two major targets in Crohn's disease or just cross-reactivity?","volume":"7","author":"Roggenbuck","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2014.11.004_bb0430","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1097\/MIB.0b013e318281f506","article-title":"Granulocyte-macrophage colony-stimulating factor autoantibodies: a marker of aggressive Crohn's disease","volume":"19","author":"Gathungu","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2014.11.004_bb0435","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1097\/MIB.0b013e31829706e0","article-title":"Increased prevalence of luminal narrowing and stricturing identified by enterography in pediatric Crohn's disease patients with elevated granulocyte-macrophage colony stimulating factor autoantibodies","volume":"19","author":"Dykes","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2014.11.004_bb0440","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/ajg.2013.360","article-title":"Granulocyte macrophage colony-stimulating factor auto-antibodies and disease relapse in inflammatory bowel disease","volume":"108","author":"D\u00e4britz","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2014.11.004_bb0445","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/MPG.0b013e3181fe2d93","article-title":"Granulocyte macrophage-colony-stimulating factor autoantibodies and increased intestinal permeability in Crohn disease","volume":"52","author":"Nylund","year":"2011","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.autrev.2014.11.004_bb0450","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.crohns.2007.10.003","article-title":"Development of pouchitis following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis: a role for serological markers and microbial pattern recognition receptor genes","volume":"2","author":"Ferrante","year":"2008","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2014.11.004_bb0455","doi-asserted-by":"crossref","first-page":"e522","DOI":"10.1016\/j.crohns.2013.03.009","article-title":"Antibodies against glycoprotein 2 are novel markers of intestinal inflammation in patients with an ileal pouch","volume":"7","author":"Werner","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2014.11.004_bb0460","doi-asserted-by":"crossref","first-page":"e602","DOI":"10.1016\/j.crohns.2013.06.010","article-title":"Anti-GP2 antibodies in inflammatory bowel disease patients with ileal pouch","volume":"7","author":"Pavlidis","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2014.11.004_bb0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/683824","article-title":"The novel Crohn's disease marker anti-GP2 antibody is associated with ileocolonic location of disease","volume":"2013","author":"Somma","year":"2013","journal-title":"Gastroenterol Res Pract"},{"key":"10.1016\/j.autrev.2014.11.004_bb0470","article-title":"Authors' response: antibodies to GP2, the major zymogen granule membrane glycoprotein, are specific for Crohn's disease and may reflect treatment response","author":"Roggenbuck","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2014.11.004_bb0475","doi-asserted-by":"crossref","first-page":"e18172","DOI":"10.1371\/journal.pone.0018172","article-title":"Characterization of changes in serum anti-glycan antibodies in Crohn's Disease \u2014 a longitudinal analysis","volume":"6","author":"Rieder","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2014.11.004_bb0480","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/ibd.20985","article-title":"Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohn's disease","volume":"16","author":"Joossens","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2014.11.004_bb0485","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1399-0039.2008.01049.x","article-title":"Interaction between seroreactivity to microbial antigens and genetics in Crohn's disease: is there a role for defensins?","volume":"71","author":"Lakatos","year":"2008","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.autrev.2014.11.004_bb0490","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1097\/MPG.0b013e318275fa77","article-title":"Glycoprotein 2 antibodies in inflammatory bowel disease: no association with disease phenotype?","volume":"56","author":"Roggenbuck","year":"2013","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.autrev.2014.11.004_bb0495","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/ibd.20778","article-title":"Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2\/CARD15 or TLR4 genotype in a Hungarian IBD cohort","volume":"15","author":"Lakatos","year":"2009","journal-title":"Inflamm Bowel Dis"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997214002766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997214002766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T19:29:29Z","timestamp":1538076569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997214002766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":99,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S1568997214002766"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2014.11.004","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review: New serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2014.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}